via National Human Genome Research Institute
Researchers from the University of Sheffield have discovered a new gene therapy pathway that has the potential to protect us against serious life-limiting diseases such as cancer and dementia
Researchers from the University of Sheffield have discovered a new gene therapy pathway that has uncovered an important regulatory mechanism to keep our genome healthy. This pathway has the potential to protect us against serious life-limiting diseases such as cancer and dementia.
Cancer and neurodegeneration are two major health challenges currently affecting the population, and they constitute two sides of the same coin – one is caused by uncontrolled cell proliferation due to genome damage, and the other is caused by excessive genome damage that causes cell death. This new pathway impacts both and offers new therapeutic opportunities to help the fight against disease.
Published in Nature Communications, the research found that when cells in our body read DNA to build proteins, they often make mistakes that can damage our genome, causing disease such as cancer and dementia. However, by investigating how cells fix damage in the DNA to keep us healthy, scientists have discovered the benefits of three proteins working together as a team. The three proteins, called USP11, KEAP1 and SETX, receive instructions from their coach to direct their function in space and time with remarkable harmony, to keep our DNA healthy.
By understanding how cells protect themselves from these mistakes and thus preventing diseases, scientists are able to modify the behaviour of these proteins to promote the health and wellbeing of people.
Findings from this study will enable scientists to develop diagnostic tests and drugs to target one or more of the proteins in the pathway for the early detection and treatment of certain types of cancer and neurological disease. Developing new drugs to regulate the level of one or more of these proteins is expected to offer new treatments for cancer and dementia.
The findings are important and significant, this is because we are now at the stage where we could make drugs to control this modification. This would be useful in killing cells, which is what we do when we treat elderly people for cancer. The other application would be to reduce the level of genome damage, which could be beneficial for other ageing associated disorders like dementia.
Original Article: New gene therapy pathway could protect us from cancer and dementia
More from: University of Sheffield
The Latest on: Gene therapy pathway
- PTC Therapeutics, Inc. (PTCT) CEO Stuart Peltz On Q2 2022 Results - Earnings Call Transcripton August 7, 2022 at 5:02 am
Q2 2022 Earnings Conference Call August 4, 2022 16:30 ET Company Participants Kylie O'Keefe - Senior Vice President, Head of Global Commercial ...
- Epigenic Therapeutics Raises $20 Million in Series Angel and Pre-A Funding to Advance Next Generation Gene Editing Therapyon August 7, 2022 at 1:00 am
Epigenic Therapeutics Co., Ltd., a frontier biotechnology company dedicated to developing next generation gene editing therapy utilizing regulation ...
- REGENXBIO Inc. (RGNX) CEO Ken Mills on Q2 2022 Results - Earnings Call Transcripton August 4, 2022 at 9:11 pm
Q2 2022 Earnings Conference Call August 03, 2022 04:30 PM ET Company Participants Vit Vasista - Chief Financial Officer Ken Mills - President & ...
- Regenxbio to file BLA using US FDA's accelerated approval pathway for RGX-121 to treat MPS IIon August 3, 2022 at 9:30 pm
Regenxbio Inc. announced its intention to file a Biologics License Application (BLA) in 2024 using the FDA's accelerated approval pathway for RGX-121 for the treatment of Mucopolysaccharidosis Type II ...
- BeiGene co-founder and ex-Viela Bio BD leader snag $200M for age-related biotech, with ARCH jumping inon August 2, 2022 at 7:29 am
Five years after forming and with more than $100 million already invested in the company, a biotech from BeiGene co-founder Xiaodong Wang is back with another whopping investment, this time at $200 ...
- Sarepta to Ask FDA to Approve DMD Gene Therapy SRP-9001on August 2, 2022 at 7:22 am
Clinical trial data showed that Sarepta Therapeutics' SRP-9001 improved motor and walking function for DMD patients three years after dosing.
- Significant step on path to developing Alzheimer's therapyon August 1, 2022 at 6:40 am
A brain protein with high potential to delay or reverse the onset of Alzheimer's disease has been exploited by University of Otago researchers.
- Sarepta to ask FDA for accelerated approval of Duchenne gene therapyon July 29, 2022 at 8:46 am
After discussions with the FDA, the biotech aims to submit an application this fall — sooner than expected and ahead of a Phase 3 study that’s now ongoing.
- Challenges in Neuroprotective Nanomedicine Development: Progress Towards Noninvasive Gene Therapy of Glaucomaon July 14, 2022 at 5:01 pm
Common approaches of neuroprotection include stimulating molecular pathways that promote neuron ... often targeted to specific ocular tissues. Gene therapy for glaucoma is a treatment that aims ...
- Nonviral Gene Therapy Harnesses IL-10, Tames Inflammationon July 12, 2022 at 8:01 am
It prevents viral gene therapy from being administered more than ... It can modulate multiple pathways by suppressing the expression of various cytokines. “We’re downregulating multiple ...
via Bing News
The Latest on: Gene therapy pathway
via Google News